Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2017 Jul 12



Publication history
Cite this article as


A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878



Minerva Medica 2017 Jul 12

DOI: 10.23736/S0026-4806.17.05320-4


language: English

Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a “real world” study by 13C-octanoic acid breath test

Gian P. CAVIGLIA 1 , Carlo SGUAZZINI 2, Fabio CISARO’ 2, Davide G. RIBALDONE 2, Chiara ROSSO 1, Sharmila FAGOONEE 3, Antonina SMEDILE 1, 2, Giorgio M. SARACCO 1, 2, Marco ASTEGIANO 2, Rinaldo PELLICANO 2

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Unit of Gastroenterology and Hepatology, Città della Salute e della Scienza, Molinette Hospital, Turin, Italy; 3 Institute for Biostructures and Bioimages CNR c/o Molecular Biotechnology Center, University of Turin, Turin, Italy


BACKGROUND: Gastric motility is a key-factor in the pathogenesis of functional dyspepsia (FD). 13C-octanoic acid breath test (OBT) is a tool used for measuring gastric emptying time in clinicalsetting. We aimed to investigate the variation in FD symptoms and OBT parameters after treatment with buspirone, amitriptyline or clebopride.
METHODS: Between Jan-2007 and Dec-2014, we enrolled 59 patients with FD unresponsive to firstling therapy with proton pump inhibitors and/or domperidone that underwent OBT before and after 3 months of buspirone (n=32), amitriptyline (n=16) or clebopride (n=11) treatment.
RESULTS: Early satiation severity was positively correlated with gastric half emptying time (t1/2) (r=0.3789, p=0.003) and gastric lag phase (r=0.3371, p=0.011), and negatively correlated with gastric emptying coefficient (r=-0.3231, p=0.015). A reduction in t1/2 measurement in association to postprandial fullness, and early satiation severity improvement was observed (p=0.009, p=0.005 and p<0.001, respectively). Patients treated with buspirone obtained both a decrease in t1/2 (p=0.005) and an amelioration in early satiation (p=0.001). Patients under amitriptyline treatment experienced an improvement in post-prandial fullness (p=0.046), whereas no variation was reported in patients treated with clebopride.
CONCLUSIONS: Patients with FD, non-responders to first-line therapy and reporting meal-related discomfort, may benefit from buspirone or amitriptyline-based therapies.

KEY WORDS: Breath test - Functional dyspepsia - Gastrointestinal motility

top of page

Publication History

Manuscript first published online: July 12, 2017
Manuscript accepted: June, 24 2017
Manuscript received: June 22, 2017

Cite this article as

Caviglia GP, Sguazzini C, Ribaldone DG, Rosso C, Fagoonee S et al. Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a “real world” study by 13C-octanoic acid breath test. Minerva Med 2017 Jul 12. DOI: 10.23736/S0026-4806.17.05320-4

Corresponding author e-mail